Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170542 | 0.70 | MAPKAPK2 (0.39) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL29396007 | 0.68 | ALDH1A1 (0.59) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL37862 | 0.68 | ALDH1A1 (0.59) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL22950 | 0.68 | — | — | |
| SCHEMBL16740702 | 0.68 | KDM4E (0.36) | ALDH1A1KDM4E | |
| SCHEMBL3281338 | 0.68 | PLAUR (0.54) | ALDH1A1CYP1A2TNKS2KDM4EGRIN2D | |
| SCHEMBL331972 | 0.67 | CA12 (0.47) | ALDH1A1CA12CA1CA3CA4 | |
| Bromide SCHEMBL7758533 | 0.67 | ALDH1A1 (0.57) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL11129386 | 0.67 | ALDH1A1 (0.57) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20597399 | 0.67 | ALDH1A1 (0.57) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | claimed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | claimed |
| EP-1720868-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2006-11-15 | — | — | EP | claimed |
| WO-2005077944-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2005-08-25 | — | — | WO | claimed |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-11 | — | — | US | claimed |
| WO-2024129931-A1 | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240197700-A1 | Methods and Compositions for Treating Lysosomal Storage Disorders | HEALTH, SANFORD | 2024-06-20 | — | — | US | disclosed |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| US-20240182503-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240174684-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC | 2024-05-30 | — | — | US | disclosed |
| EP-4370113-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | Avanti Biosciences Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240148716-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | DUKE UNIVERSITY (US) | 2024-05-09 | — | — | US | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| EP-2291187-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2011-03-09 | — | — | EP | disclosed |
| WO-2009132238-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-08-06 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1720868-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077944-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | MAPKAPK2 1206/4885RPS6KA3 2643/4885CSNK2A1 4211/4885 |
| US-20240174684-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | CGAS, STING1, IRF3 | MAPKAPK2 1282/4885RPS6KA3 1001/4885CSNK2A1 239/4885 |
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | ALK, ALKBH5, ALKBH3 | MAPKAPK2 1593/4885RPS6KA3 4693/4885CSNK2A1 3698/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | MAPKAPK2 831/4885RPS6KA3 633/4885CSNK2A1 1348/4885 |
| US-20240182503-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | CFB, CFH, C9 | MAPKAPK2 840/4885RPS6KA3 1101/4885CSNK2A1 2095/4885 |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | MAPKAPK2 1225/4885RPS6KA3 2966/4885CSNK2A1 4202/4885 |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | MAPKAPK2 1394/4885RPS6KA3 3213/4885CSNK2A1 3002/4885 |
| US-20240197700-A1 | Methods and Compositions for Treating Lysosomal Storage Disorders | GAA, GBA1, MAN2B1 | MAPKAPK2 2893/4885RPS6KA3 1138/4885CSNK2A1 1134/4885 |
| US-20240148716-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | TP53, PLK1, NRAS | MAPKAPK2 877/4885RPS6KA3 395/4885CSNK2A1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.